AZD5985 Single ascending dose study
Study identifier:D2300C00002
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Terminated/Withdrawn
Official Title
A Phase I, Single Centre, Double-blind, Randomised, Placebo-controlled, Parallel-group Study to Assess the Safety, Tolerability and Pharmacokinetics of Single Ascending Oral Doses of AZD5985 in Healthy Male Subjects
Medical condition
Healthy
Phase
Phase 1
Healthy volunteers
Yes
Study drug
AZD5985, Placebo
Sex
Male
Actual Enrollment
72
Study type
Interventional
Age
18 Years - 45 Years
Date
Study Start Date: 01 Aug 2009
Primary Completion Date: -
Estimated Study Completion Date: 01 Nov 2009
Study design
Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Basic Science
Verification:
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Experimental: A AZD5985 | Drug: AZD5985 Single dose-The starting dose will be 40 mg, oral suspension, with up to 8 dose escalations not exceeding AstraZeneca predefined upper exposure limits |
| Placebo Comparator: B Placebo | Drug: Placebo Oral suspension |
Contacts
Investigators
Principal Investigator
Eva Pettersson
AstraZeneca R&D, Lund, Sweden
